Acquisition by Khan Ruhi Ahmad of 131000 shares of Caribou Biosciences at 6.12 subject to Rule 16b-3

CRBU Stock  USD 2.20  0.18  8.91%   
Slightly above 56% of all Caribou Biosciences' private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Caribou Biosciences suggests that some traders are interested. Caribou Biosciences' investing sentiment can be driven by a variety of factors including economic data, Caribou Biosciences' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Caribou Biosciences Officer Chief Business Officer. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 131000 option to purchase common stock at 6.12 of Caribou Biosciences by Khan Ruhi Ahmad on 1st of October 2024. This event was filed by Caribou Biosciences with SEC on 2023-02-21. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Caribou Biosciences' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Caribou Biosciences' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Caribou Biosciences Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Caribou Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Caribou Biosciences Fundamental Analysis

We analyze Caribou Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Caribou Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Caribou Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash And Equivalents

Cash And Equivalents Comparative Analysis

Caribou Biosciences is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Caribou Biosciences Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Caribou Biosciences stock to make a market-neutral strategy. Peer analysis of Caribou Biosciences could also be used in its relative valuation, which is a method of valuing Caribou Biosciences by comparing valuation metrics with similar companies.

Peers

Caribou Biosciences Related Equities

FATEFate Therapeutics   18.28   
0%
100.0%
VERVVerve Therapeutics   8.85   
0%
48.0%
BEAMBeam Therapeutics   5.26   
0%
28.0%
SANASana Biotechnology   4.08   
0%
22.0%
NTLAIntellia Therapeutics   3.26   
0%
17.0%
CRSPCrispr Therapeutics   3.10   
0%
16.0%
ADPTAdaptive Biotechnologies   0.88   
0%
4.0%
EDITEditas Medicine   0.45   
2.0%
0%
PRMEPrime Medicine,   1.20   
6.0%
0%

Additional Tools for Caribou Stock Analysis

When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.